Jotul Holdings SA Interim financial report - Half-year ended 30 June 2020
November 06, 2020 07:00 ET
|
Jøtul AS
In the first half of 2020, the Jotul Group reached a consolidated profit of MNOK -68.5 (H12019: MNOK -46.9). The operating result totaled MNOK -60.1 in H1 2020 (H1 2019: MNOK -16.7). The 2020 total...
Infant Bacterial Therapeutics AB Infant Bacterial Therapeutics AB (publ), (IBT) Delårsrapport 1 januari – 30 september 2020
November 05, 2020 02:00 ET
|
Infant Bacterial Therapeutics AB
VD Kommenterar IBT utvecklar läkemedelskandidaten IBP-9414 för att förebygga nekrotiserande enterokolit (”NEC”), samt förbättra så kallad “feeding tolerance” hos för tidigt födda barn....
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – September 30, 2020
November 05, 2020 02:00 ET
|
Infant Bacterial Therapeutics AB
Message from the CEO IBT is currently developing its lead drug candidate IBP-9414 to prevent necrotizing enterocolitis (NEC), and to improve so-called "feeding tolerance" in premature infants....
Ergomed plc Interim results for the six months ended 30 June 2020
September 22, 2020 07:00 ET
|
Ergomed plc
PRESS RELEASE Interim results for the six months ended 30 June 2020 Services strategy drives revenue and profit growthOrder book growth underpins high forward visibility Total revenue growth of...
Auris Medical Provides Business Update and Reports First Half 2020 Financial Results
September 17, 2020 08:00 ET
|
Auris Medical AG
Advancing Phase 2 trial with AM-125 in acute vertigo based on positive interim dataPositive outcome from AM-201 trial in prevention of antipsychotic-induced weight gainAddition of new intranasal...
Infant Bacterial Therapeutics AB Infant Bacterial Therapeutics AB (publ), (IBT) Delårsrapport 1 januari – 30 juni 2020
August 14, 2020 02:00 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB Infant Bacterial Therapeutics AB (publ), (IBT) Delårsrapport 1 januari – 30 juni 2020 VD Kommenterar IBT utvecklar läkemedelskandidaten IBP-9414 för att...
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – June 30, 2020
August 14, 2020 02:00 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – June 30, 2020 Message from the CEO IBT is currently developing its drug candidate IBP-9414 to prevent necrotizing...
Årsstämma i Infant Bacterial Therapeutics
June 16, 2020 11:00 ET
|
Infant Bacterial Therapeutics AB
Årsstämma i Infant Bacterial Therapeutics På årsstämman i Infant Bacterial Therapeutics AB (publ) den 16 juni 2020 beslöts bland annat följande: fastställande av årsredovisningenbeviljad...
Annual General Meeting of Infant Bacterial Therapeutics
June 16, 2020 11:00 ET
|
Infant Bacterial Therapeutics AB
At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on June 16, 2020, among other things, the following was resolved: adoption of the annual reportdischarge from liability...
Infant Bacterial Therapeutics AB Infant Bacterial Therapeutics AB (publ), (IBT) Delårsrapport 1 januari – 31 mars 2020
May 11, 2020 10:00 ET
|
Infant Bacterial Therapeutics AB
VD kommenterarIBT utvecklar läkemedelskandidaten IBP-9414 för att minska förekomsten av nekrotiserande enterokolit (”NEC”), samt förbättra så kallad “feeding tolerance” hos för tidigt födda...